Joe Montana chats with Mackenzie Salmon about his partnership with Pfizer and how he keeps himself healthy now that he's over ...

The full results from Pfizer’s pivotal study of its Duchenne muscular dystrophy gene therapy show patients saw no significant ...

H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.

A woman was charged with trespassing on school property after a dispute with a school bus driver in Newport News on Oct. 10, police said.

Global Hemostasis Products MarketThe global hemostasis products market is poised for substantial growth, with an estimated valuation of USD 1.58 billion in 2023 and projected to exceed USD 2.65 ...

Wilson explains how Pfizer's decision to withdraw Oxbryta from global markets could affect the sickle cell community.

Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's NMPA for a specific type of NSCLC.

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

All the companies have skin in the game for clotting/bleeding disorders. The BMS-Pfizer Alliance market Factor Xa blood ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

In the assessment of 12-month price targets, analysts unveil insights for ICU Medical, presenting an average target of $169.5 ...